![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Efficacy of MK-8591 Against Diverse HIV-1 Subtypes and NRTI-Resistant Clinical Isolates
|
|
|
Reported by Jules Levin
HIV Drug Therapy, Glasgow 2018, October 28-31, 2018, Glasgow
J.A. Grobler; Q. Huang;D.J. Hazuda; M.-T. Lai
Merck & Co., Inc., Kenilworth, NJ, USA
![1031181](../images%20/103118/103118-1/1031181.gif)
![1031182](../images%20/103118/103118-1/1031182.gif)
![1031183](../images%20/103118/103118-1/1031183.gif)
![1031185](../images%20/103118/103118-1/1031185.gif)
![1031186](../images%20/103118/103118-1/1031186.gif)
![1031187](../images%20/103118/103118-1/1031187.gif)
![1031188](../images%20/103118/103118-1/1031188.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|